Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 1;52(4):618-625.
doi: 10.1097/CCM.0000000000006114. Epub 2023 Nov 13.

Pharmacotherapy for Reducing RBC Transfusion for Patients in the ICU: A Systematic Review and Network Meta-Analysis

Shodai Yoshihiro  1   2 , Takashi Hongo  3 , Mariko Yamamoto  4 , Shunsuke Taito  2   5 , Yuki Kataoka  2
Affiliations

Pharmacotherapy for Reducing RBC Transfusion for Patients in the ICU: A Systematic Review and Network Meta-Analysis

Shodai Yoshihiro et al. Crit Care Med. .

Abstract

Objectives: To determine optional therapeutic strategies by comparing monotherapies and combination therapies to reduce RBC transfusion requirement for patients in the ICU.

Data sources: MEDLINE, CENTRAL, and Embase were searched for studies published from database inception until July 2023.

Data extraction: We included randomized controlled trials comparing erythropoiesis-stimulating agents (Epo), iron, combination therapy with iron and Epo, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vitamin D 3 (VD3), and placebo/no treatment. A frequentist network meta-analysis (NMA) was performed using a random effects model, and the confidence in NMA was rated.

Data synthesis: Of 117 eligible studies, 75 studies (15,091 patients) were included in the quantitative analysis. Compared with placebo/no treatment, the combination therapy reduces the requirement for RBC transfusion (risk ratio [RR]: 0.60; 95% CI, 0.49-0.74; confidence rating: moderate). The Epo or iron monotherapy may reduce the requirement for RBC transfusion (RR: 0.81; 95% CI, 0.63-1.04; confidence rating: low; RR: 0.83; 95% CI, 0.70-0.98; confidence rating: low, respectively). Combination therapy may not increase the prevalence of both venous thromboembolism (VTE) (RR: 0.73; 95% CI, 0.25-2.08; confidence rating: low) and infection. Epo monotherapy may not increase the prevalence of VTE but may increase that of infections (RR: 1.27; 95% CI, 0.94-1.73; confidence rating: low). Iron monotherapy may not increase the prevalence of both VTE and infection. Evidence for VD3 and HIF-PHI remains uncertain.

Conclusions: Combination therapy with iron and Epo likely reduces the requirement for RBC transfusion and may be less harmful than other therapies.

PubMed Disclaimer

Conflict of interest statement

Dr. Yamamoto disclosed work for hire. The remaining authors have disclosed that they do not have any potential conflicts of interest.

References

    1. Warner MA, Hanson AC, Frank RD, et al.: Prevalence of and recovery from anemia following hospitalization for critical illness among adults. JAMA Netw Open 2020; 3:e2017843
    1. Bosboom JJ, Klanderman RB, Migdady Y, et al.: Transfusion-associated circulatory overload: A clinical perspective. Transfus Med Rev 2019; 33:69–77
    1. Rohde JM, Dimcheff DE, Blumberg N, et al.: Health care-associated infection after red blood cell transfusion: A systematic review and meta-analysis. JAMA 2014; 311:1317–1326
    1. Lasocki S, Pène F, Ait-Oufella H, et al.: Management and prevention of anemia (acute bleeding excluded) in adult critical care patients. Ann Intensive Care 2020; 10:97
    1. Vlaar AP, Oczkowski S, de Bruin S, et al.: Transfusion strategies in non-bleeding critically ill adults: A clinical practice guideline from the European Society of Intensive Care Medicine. Intensive Care Med 2020; 46:673–696

Publication types